According to the president of the American Academy of Anti-Aging Medicine, Dr. Ronald Klatz, "The body-building action of GH has now been shown in many different groups, including athletes, healthy young untrained men, GH-deficient adults, and elderly men." When the GH therapy is stopped, the benefits slowly decline.

Dr. Edmund Chein even makes it a point to not talk about "fat" with his patients because "we talk about percentage of fat and percentage of lean muscle. You are reversing, losing fat and gaining lean muscle. Your net weight may stay the same or even go up."

In a recent BBC article, they identify HGH as being potentially the next "Sports Menace".

Why? In their article titled "Human growth hormone explained," the BBC points out the potential muscle building and performance enhancing capabilities of GH. Their concern lies in the fact ".. it is almost impossible to set a blood level of GH that would be considered unnaturally high and indicative of doping, because levels of naturally-occurring GH can vary by more than 100-fold in response to factors such as nutritional state, sleep and exercise."
Regardless of perspective, the one thing all three of these sources agree on is clear. They all agree upon the benefits of GH for muscle building as well as athletic performance.

G.H., Is it the Master Hormone of Youth?

As medicine enters the 21st century, there is growing recognition from physicians, clinicians and biomedical researchers that human lifespan can be prolonged and that premature deterioration from things such as cardiovascular disease, cancer, diabetes, stroke and neurodegenerative disorders such as Alzheimer's and Parkinson's may be delayed and prevented. At the center of much of this research is H.G.H. or Human Growth Hormone.

The following is a direct quote from the American Academy of Anti-Aging Medicine web-site.

"While most people think of GH as the miraculous treatment for children doomed to dwarfism (over the past 30 years it has saved tens of thousands from this fate). HGH therapy has been so effective for our young that a remake of The Wizard of Oz is nearly impossible today, due to this medical achievement.

The next great benefit of HGH therapy appears to be in the aging population.

People with age related deficiency of GH become fat, flabby, frail, and lethargic, lose interest in sex, have trouble sleeping, concentrating, remembering things, tire easily, and in general, lose their zest for life.

With HGH, all these so-called signs of aging are reversed."

Aging and the natural decline of Growth Hormone production!

When Dr. Daniel Rudman, a pioneer researcher and his colleagues at the Medical College of Wisconsin published their article in the prestigious New England Journal of Medicine they broke new ground in the field of anti-aging medicine.

It was the first clinical trial of elderly men on GH, comparing the effects of six months' of GH injections on twelve men, ages sixty-one to eighty-one, with an age-matched control group. Their results made headlines all over the world. Those taking the hormone injections gained an average of 8.8 percent in lean body mass and lost 14 percent in fat, without diets or exercise. Their skin became thicker and firmer and the lumbar bones of the spine increased.

Published in the New England Journal of Medicine, the researchers wrote: "The effects of six months of human growth hormone on lean body mass and adipose-tissue mass were equivalent in magnitude to the changes incurred during 10 to 20 years of aging."

It's important to realize, HGH declines with age in every animal species that has been evaluated to date.

In humans, the amount of GH after ages twenty-one to thirty-one falls about 14 percent per decade, so that the total twenty-four-hour GH production rate is reduced in half by age sixty. In numerical values, on a daily basis we produce about 500 mcg (micrograms) at age twenty, 200 mcg at age forty, and 25 mcg at age eighty. The fall in IGF-1 with an increase in age mirrors that of HGH.

Did you know? Dr. Rudman considered plasma IGF-1 levels under 350 evidence of a deficiency.

CLICK HERE: Published HGH Studies from the New England Journal of Medicine

Unsure about your Growth Hormone levels?
Order an accurate Blood or Saliva Test!

Between the ages of twenty and forty years, fewer than 5 percent of healthy men have IGF-1 levels lower than 350.
According to Dr. Ronald Klatz and Dr. Robert Goldman of the American Academy of Anti-Aging Medicine, ".. after age sixty, 30 percent of apparently healthy men have this low amount. And after age sixty-five, about half the population is partially or wholly deficient in GH."

We recommend reading Eli Lilly's own safety information at http://www.humatrope.com/common_pages/prescribing_information.jsp

Need Syringes? Please click here to visit www.getpinz.com
the best online source for high quality syringes.

HUMATROPE ® GH Information

Elli Lilly Humatrope prescribing information!
Follow this link to the Elli Lilly Company HGH page.
http://pi.lilly.com/us/humatrope-pi.pdf

Humatrope Ingredients:
Each bottle contains 15 IU (5mg) of biosynthetic human growth hormone (from recombinant DNI), excipients include Glycine, mannitol, bibasic sodium phosphate. Each bottle of diluent contains m-cresol, glycerin and water for injections.

Pharmaceutical Classification of Humatrope:
Sterile freeze-dried powder of systemic hormone preparation.

Directions for usage of Humatrope:
Long-term treatment for stunted growth, due to the reduction or lack of somatotrophic endogenous hormone secretion in-patients who have not yet finished puberty. Treatment of short stature in girls suffering from Turner’s syndrome confirmed by chromosomal analysis (the effect on final height has not yet been established).

Contraindications using Humatrope:
Hypersensitivity in certain patients to the product or any of its ingredients. Patients with complete knitting of the epiphyses. Diabetes mellitus. Humatrope should not be used if there is any sign of active neoplasms. Endocrane lesions must be inactive and anti-tumoral treatment finished before beginning hormonal treatment. The use of Humatrope must be interrupted in the event of renewed tumoral growth. Humatrope must not be reconstituted with the accompanying diluent if the patient is sensitive to m-cresol or glycerin.

Precautionary measures in the usage of Humatrope:
Humatrope treatment should only be carried out under a doctor’s authorization, by prescription, by university medical centers or hospitals specializing in the treatment of patients with growth hormone deficiency. Diagnoses must be confirmed before beginning Humatrope injections. This requires a clinical examination of the patient with detailed case histories, particularly with regard to auxilogical evaluations and the carrying out of laboratory tests, including stimulus test, to verify hypophysial hypothalamus functioning. Humatrope therapy should be carried out by a specialist in the diagnosis and treatment of patients related to stunted growth. Patients who, following diagnosis, undergo treatment with the somatotrophic hormone will have to be inscribed in a regional register and monitored by means of clinical auxilogical and laboratory evaluations every six months to check the functioning of the thyroid, glucide metabolism etc. The lack of available information may mean the exposure of the patient to a risk, which may exceed the therapeutic benefit obtained. Human hormone growth treatment should be complemented by an adequate supply of calories and amino acids. Once reconstituted with the accompanying diluent, Humatrope can be taken in subcutaneous or intramuscular injections.

Carcinogenesis, Mutagenesis and Fertility Alterations using Humatrope:
Long term studies with Humatrope on animals have not been carried out, which would enable the evaluation of any carcinogenic or fertility altering effect which this pharmaceutical product may possibly have. No mutagenic effect due to Humatrope has been seen in tests up to the present.

Using Humatrope during pregnancy and nursing:
Studies on Humatrope and its effects on animal reproduction have not been carried out. It has not been seen that Humatrope can harm the fetus during pregnancy, nor that it can affect reproduction. Nevertheless, Humatrope should only be taken during pregnancy if absolutely necessary. Studies of the effects of Humatrope on nursing mothers have not been carried out and hence it is not known whether this product is excreted into mother’s milk. However, since many pharmaceutical products are indeed passed into mother’s milk, nursing mothers are advised to take Humatrope with extreme caution.

Interactions using Humatrope:
Since taking Humatrope may cause resistance to insulin, patients should undergo periodic check ups in order to detect any intolerance to glucose. Children suffering from diabetes mellitus should be carefully supervised during Humatrope treatment, as it may be necessary to increase their insulin dosage. Excessive glucocortoid treatments may inhibit the effect of growth stimulation provided by the human somatotrophic hormone. In the case of patients who also suffer from ACTH (adrenocrticotrophic hormone) deficiency, the substitutive dosage of glucocorticoids must be accurately regulated in order to prevent any inhibitory effect on growth.

Please be advised when using Humatrope:
Attentive and constant supervision by the specialist is advised during growth hormone treatment of patients with neoplasms in remission. Those with a shortage of the growth hormone accompanying an endocrane lesion must be checked particularly frequently so as to prevent spreading or a relapse. Patients with growth hormone deficiency may frequently show alterations having to do with the epiphysis. For this reason, children who limp or show unsteadiness in their walking during growth hormone treatment should have thorough check ups. Hypothyroidism may arise during Humatrope treatment. Because untreated hypothyroidism can prevent an optimal response to Humatrope, patients should have periodic tests for thyroid functioning and undergo thyroid hormone treatment when necessary. Patients with psoriasis are also advised to have regular check ups so as to avoid a possible aggravation of the condition. In the event of sensitivity to the accompanying diluent, the bottles may be reconstituted with sterile water for injections. If Humatrope is reconstituted this way, the solution must be administered within 24 hours and any left over solution thrown away. If, once reconstituted, the solution is not administered immediately, it may be kept up to 24 hours in the refrigerator at a temperature between +2 degrees Celsius and +8 degrees Celsius. Humatrope’s effect on the patient’s capacity to drive or operate machinery has not been determined. back to top

Directions for usage of Humatrope:
Dosage and duration of treatment are to be decided by the specialist according to the needs of the patient.

Patients using Humatrope for growth hormone deficiency:
The recommended subcutaneous or intramuscular dosage is 0.18 mg/ kg of body weight (0.48 IU/ Kg) per week, approximately equivalent to 12 IU/m2 per week. The weekly dosage is to be divided into either 3 intramuscular injections or 6 to 7 subcutaneous injections.

Patients with Turner’s syndrome administering Humatrope:
The recommended dosage is 0.3- 0.34 mg/ Kg of body weight (0.8- 0.9 IU/ Kg) per week, equivalent to 24- 28 IU m2 per week. The weekly dosage is to be divided into 6-7 subcutaneous injections, to be administered preferably in the evening. With subcutaneous injection, it is advised that the place of injection be varied so as to avoid the onset of lipoatrophy. To prepare the Humatrope solution: Inject 0.5- 2ml of the diluent into the bottle containing the freeze-dried powder, directing the flow of the liquid towards the sides of the bottle. Then shake the bottle with a gentle rotating movement until the contents are completely dissolved. DO NOT SHAKE VIGOROUSLY. The use of sterile syringes and needles are recommended for the injections. After reconstitution, the solution must be transparent and without precipitates. If it is opalescent or has precipitates, then it MUST NOT be used. Clean the surface of the bottle’s rubber stopper with antiseptic before and after using it to prevent contaminating its contents. Syringes must have a volume small enough to enable the prescribed dosage to be extracted with reasonable accuracy. back to top

Directions for reconstitution and administration of Humatrope:
Do not reconstitution or administer this pharmaceutical product without first receiving adequate instructions as to the correct technique by the specialist. Follow the doctor’s sterilizing technique by the specialist. Follow the doctor’s sterilizing technique. Destroy and get rid of syringes or needles following each use. Humatrope must be kept in a cool place (from +2 degrees Celsius to +8 degrees Celsius) after reconstitution (refrigerator). DO NOT FREEZE. ONCE RECONSTITUTED, HUMATROPE MUST BE USED WITHIN 21 DAYS.

Reconstitution of the Humatrope bottle:
Reconstitute Humatrope only with Humatrope diluent. Do not use any other solution for reconstitution unless it is by your doctor’s prescription. The doctor will also decide the correct sizes of the syringe and needle and the amount of diluent to add to the Humatrope bottle. ALWAYS WASH YOUR HANDS FIRST
Remove and throw away the stoppers of the bottles of diluent and of Humatrope. Clean the rubber covering of the bottles with cotton wad soaked in alcohol (see figure 1 in pack). Remove the protective covering of the needle and set it aside. Pull the piston of the syringe until the same volume of air is let in as the volume of diluent prescribed by the doctor. Insert the needle into the rubber stopper of the bottle of diluent and inject air into the bottle.
Holding the bottle upside down and making sure that the needlepoint is in the solution, extract the amount of diluent prescribed by the specialist (see figure 2 in pack). Once you are sure there are no air bubbles left in the syringe, turn the bottle right side up and extract the syringe, taking care that the position of the piston does not change.
Insert the same needle into the bottle of Humatrope and gently turn the needle point inwards towards the side of the bottle. Slowly inject the diluent, directing the flow towards the side (see figure 3 in pack). DO NOT AIM IT IN THE DIRECTION OF THE WHITE POWDER AT THE BOTTOM OF THE BOTTLE. To balance the pressure and before removing the syringe from the bottle, let in a volume of air equal to that of the diluent just added. If the needle can become separated from the body of the syringe, remove, destroy and throw it away. If the needle and the syringe cannot be separated, eliminate the entire unit.
Shake the bottle with a gentle rotating movement until the contents are completely dissolved (see figure 4 in pack).
Preparing the Humatrope injections:
Do not use Humatrope, if upon reconstitution, it is opalescent or contains precipitates.
If the needle can be separated from the syringe, apply a new needle before giving the injection. If the syringe and needle from an inseparable unit use another syringe for the preparation of the injection.
Before and after administrating the injection, the rubber stopper of the bottle must be cleaned with alcohol or an alcohol based antiseptic solution to avoid that repeated insertions of the needle contaminate the contents.
Remove the cover of the needle and let an amount of air equal to the amount of Humatrope into the syringe.
Insert the cover of the bottle of reconstituted Humatrope and inject air into the bottle. Turn the bottle upside down and making sure that the needlepoint is in the solution, inject the exact dosage (see figure 2 in pack). Make sure that there are no air bubbles in the syringe.
Remove the syringe and wrap up the needle. Write down the date of reconstitution on the label of the bottle and eliminate any diluent, which has not been used.
Put the unused part of reconstituted Humatrope in the refrigerator and use it within 21 days.
Destroy the needle or syringe needle unit once finished.
Humatrope Injections:
Tap the spot chosen for the injection gently with one finger.
Carefully clean the area with a cotton wad, which has been soaked in alcohol, making a circular movement, moving from the inside of the circle outward.

Subcutaneous injections. Stabilize the skin between the thumb and the index finger and raise an ample portion of skin. Holding the needle at a 90-degree angle to the spot chosen for the injection, insert the entire needle into the skin. Slowly inject the liquid. Remove the needle quickly, exerting pressure on the place chosen for the injection with a dry gauze pad or a cotton wad. Rub for several seconds. Destroy the needle or the needle, syringe unit.

Intramuscular injections. With the thumb and first two fingers, press firmly against an ample portion of muscle mass, such as the thigh. Holding the syringe at a 90-degree angle to the spot chosen for the injection, insert the entire needle into the skin. Holding the needle inside the place chosen for injection, slowly pull back the piston. Should blood appear in the syringe, remove the needle, throw out the syringe with the pharmaceutical product and prepare another injection. If blood does not enter the syringe, slowly inject the solution. Pull the needle out quickly, exerting pressure on the place of injection with a dry gauze pad or cotton wad. Rub for several seconds. Destroy the needle or the needle/ syringe unit when finished. If you are in any doubt, consult your doctor.
In case of overdose using Humatrope:
Overdose may cause hypoglycemia followed by hyperglycemia. Long term overdose may result in symptoms of acromegaly, similar to the effects of an excess of human somatotrophic hormone.

Humatrope Side Effects:
In the course of clinical research studies on patients with growth hormone deficiency, which has never been treated on patients with Turner’s syndrome, a development of antibodies against the growth hormone, has been detected, but which has no effect on the rhythm of growth. Up to the present, long term effects caused by the presence of these antibodies have not been noted. Research into antibodies against the growth hormone should be carried out on all subjects who fail to respond to treatment. High doses of Humatrope deliberately given to healthy adults have on rare occasions produced the following effects- headache, local muscular pain, weakness, mild hypoglycemia and glycosuria. In studies on children with growth hormone deficiency, rare cases have been reported of pain in the area of the injection. 2.5% of those children treated has shown mild transitory oedema in the early stages of treatment. Should the patient notice any unpleasant side effect not described in this leaflet, he should consult his specialist or family doctor. Attention- Do not use this or any medicine once its expiry date has passed.

Special notes on storage of Humatrope:
Store in the refrigerator at +2 degrees Celsius to +8 degrees Celsius after reconstitution. Keep the diluent and the reconstituted product from freezing. If reconstituted with the accompanying diluent, the product may be kept for 21 days in the refrigerator without significant loss of properties.

Serano Labs - Legal Statement

No Warranty
Information accessed through this website is presented in summary and interactive form and is not exhaustive. SERONO will make reasonable efforts to include accurate and current information, wherever possible, but makes no warranties or representations as to its accuracy or completeness. This information is provided "as is" without warranty of any kind, either express or implied, including but not limited to implied warranty of fitness for particular purpose.

In no event shall any member of the Serono group of companies or its affiliates or respective employees be liable for any damages whatsoever resulting from or arising out of or in connection with the use or performance of this website. Some jurisdictions do not allow exclusion of implied warranties so the above exclusion may not apply to you. The information may refer to pharmaceutical products or therapeutic indications not yet registered or approved in a given country where Serono is present.

Individual usage of medical products
The information provided via this website concerning medical products is not complete and should not be used as a substitute for a consultation or visit with a physician or other healthcare provider.

Should you have any health care related questions, please see your physician or other healthcare provider promptly.

Non-commercial use
SERONO.COM gives you permission to copy text or documents published herein on the World-wide Web for non-commercial use only, provided any copy of these documents that you make shall retain all copyright and other proprietary notices contained herein.

GENOTROPIN

In adults, GENOTROPIN is prescribed for growth hormone deficiency (GHD) that started either in childhood or as an adult. Your doctor will do tests to show if you have GHD.

Important Safety Information

Growth hormone (GH) therapy should not be used in patients with cancer or who are receiving cancer treatment. GH should not be used to increase height in children after the growth plates have closed.

GH should also not be started in patients who are ill because of surgery, trauma, or respiratory failure.

GH should not be used in children with PWS who are severely overweight or have severe breathing problems.

The 5.8-mg and 13.8-mg cartridges of GENOTROPIN Lyophilized Powder contain m-Cresol and should not be used by patients allergic to it.

Deaths have been reported with the use of growth hormone in children with PWS. These children were extremely overweight, had breathing problems, and/or lung infection. All patients with PWS should be examined for these problems. They should also establish healthy weight control.

If the patient has diabetes, insulin dosage may need to be adjusted during therapy with GENOTROPIN.

Be sure to tell the doctor about any drugs the patient is taking.

Tell the doctor if your child begins to limp or has hip or knee pain while taking GENOTROPIN.

In children experiencing rapid growth, curvature of the spine (scoliosis) may worsen.

A small number of patients treated with GENOTROPIN have had increased pressure in the brain. Be sure to tell the doctor if symptoms of this occur, such as headache, visual changes, and nausea and/or vomiting.

If the patient is pregnant or nursing, talk to the doctor.

In studies of GENOTROPIN in children with GHD, side effects included injection site reactions, such as pain, redness/swelling, inflammation, bleeding, scaring, lumps, or rash. Other side effects were fat loss, headache, blood in the urine, low thyroid activity, and mildly increased blood sugar.

In studies of GENOTROPIN in children with PWS, side effects included fluid retention, aggressiveness, joint and muscle pain, hair loss, headache, and increased pressure in the brain.

In studies of GENOTROPIN in children born SGA, side effects included temporarily elevated blood sugar, increased pressure in the brain, early puberty, abnormal jaw growth, injection site reactions, growth of moles, and worsening of scoliosis (curvature of the spine).

In studies of GENOTROPIN in adults with GHD, side effects included fluid retention, joint or muscle pain, stiffness, and changes in sensation. These events usually went away with time.

Tell the doctor about these or any other side effects that you notice.

Please read Full Prescribing Information.

hgh human growth hormone research Clinical Studies

G.H., Is it the Master Hormone of Youth?

Aging and the natural decline of Growth Hormone production!